Biocon Expects H2 Boost from Biosimilars, Insulin

What happened

Biocon expects the second half of fiscal 2027 to outperform the first, citing US sales of biosimilars ustekinumab and aflibercept, planned pertuzumab launches in Europe and Brazil, and growing insulin demand. Its second-quarter net profit fell 52% year over year, while quarterly revenue rose 2% to 4,389 crore.

Confirmed

Global impact / market context

The expected improvement depends on products reaching customers and gaining demand: delayed shipments kept some second-quarter sales from being recorded even though their costs were booked. If launches and deliveries proceed, revenue recognition could catch up and support results; further delays could keep costs ahead of reported sales.

Analyst inference

The quarter showed mixed performance: revenue increased, but net profit fell sharply and EBITDA, a measure of operating earnings before interest, taxes, depreciation and amortisation, declined 7%, with its share of revenue falling to 20% from 22%. Shipment timing partly explains the gap, while the article also cites geopolitical disruption.

Confirmed

What to watch

1. Track whether the company reports stronger second-half performance and how much comes from the named US biosimilars, European and Brazilian pertuzumab launch, and insulin demand. Analyst inference
2. Watch for evidence that shipments and sales recognition remain on schedule; delayed delivery can defer reported revenue even when related costs have already been recorded. Analyst inference
3. Check whether the next results show improvement in quarterly profit and EBITDA, alongside revenue growth, to judge whether the second-half expectation is translating into broader operating gains. Analyst inference

Evidence

• Original source link unavailable